<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2805">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542408</url>
  </required_header>
  <id_info>
    <org_study_id>HERO-19</org_study_id>
    <nct_id>NCT04542408</nct_id>
  </id_info>
  <brief_title>Hamburg Edoxaban for Anticoagulation in COVID-19 Study</brief_title>
  <acronym>HERO-19</acronym>
  <official_title>Hamburg Edoxaban for Anticoagulation in COVID-19 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of&#xD;
      standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate&#xD;
      anticoagulation strategy = low-dose low-molecular weight heparin [LMWH], ambulatory no&#xD;
      anticoagulation, i.e. placebo within this trial) in reduction of morbidity and mortality&#xD;
      endpoints in patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coagulopathy in the context of COVID-19 is a major threat to affected patients due to deep&#xD;
      vein thromboses and pulmonary embolisms. Actual data show an unexpectedly high incidence of&#xD;
      partially fatal complications without any prior clinical evidence in some cases. Therefore,&#xD;
      this prospective, randomized, assessor-blinded, multicenter, placebo-controlled,&#xD;
      interventional trial will investigate whether therapeutic anticoagulation on top of SOC&#xD;
      compared to prophylactic anticoagulation as part of SOC- can improve objective&#xD;
      patient-relative endpoints, relevant for prognosis in patients with COVID-19. 172 eligible&#xD;
      patients will be randomized 1:1 to experimental or control group. Patients enrolled to&#xD;
      experimental group will receive therapeutic anticoagulation using LMWH body weight-adapted&#xD;
      during course of hospital stay and oral anticoagulation using Edoxaban according to SmPC&#xD;
      (60mg once a day) after being discharged from hospital / outpatient course. Patients enrolled&#xD;
      to control group will receive prophylactic anticoagulation using LMWH as part of SOC whilst&#xD;
      inpatient course, and placebo after discharge / outpatient course. Patients will be informed&#xD;
      of their allocation to the placebo group, as it has been shown that the effect of placebo is&#xD;
      still detectable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint: all-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism</measure>
    <time_frame>42 days</time_frame>
    <description>All-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism during follow-up (42 days). Thromboembolisms will be detected by duplex ultrasonography of arms and legs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>42 days</time_frame>
    <description>All-cause mortality during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality related to venous thromboembolism</measure>
    <time_frame>42 days</time_frame>
    <description>Mortality related to venous thromboembolism during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality related to arterial thromboembolism</measure>
    <time_frame>42 days</time_frame>
    <description>Mortality related to arterial thromboembolism during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of venous and/ or arterial thromboembolism</measure>
    <time_frame>42 days</time_frame>
    <description>Rate of venous and/ or arterial thromboembolism during follow-up (42 days) Thromboembolisms will be detected by duplex ultrasonography of arms and legs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and length of mechanical ventilation</measure>
    <time_frame>42 days</time_frame>
    <description>Rate and length of mechanical Ventilation during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of initial stay at ICU after application of IMP</measure>
    <time_frame>42 days</time_frame>
    <description>Length of initial stay at ICU after application of IMP during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalisation</measure>
    <time_frame>42 days</time_frame>
    <description>Rehospitalisation during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and length of renal replacement therapy</measure>
    <time_frame>42 days</time_frame>
    <description>Rate and length of renal replacement therapy during follow-up (42 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac arrest/ CPR</measure>
    <time_frame>42 days</time_frame>
    <description>Cardiac arrest/ CPR during follow-up (42 days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Intensive anticoagulation strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-hospital (ICU &amp; normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate anticoagulation strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In-hospital (ICU &amp; normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral placebo according to the dosing rules for Edoxaban</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation Agents (Edoxaban and/or high dose LMWH)</intervention_name>
    <description>In-hospital (ICU &amp; normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until</description>
    <arm_group_label>Intensive anticoagulation strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Low molecular weight heparin or Placebo</intervention_name>
    <description>In-hospital (ICU &amp; normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban</description>
    <arm_group_label>Moderate anticoagulation strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of COVID-19 and hospitalization on ICU, or&#xD;
&#xD;
          -  Diagnosis of COVID-19 and hospitalization on normal ward, or&#xD;
&#xD;
          -  Diagnosis of COVID-19 (within 10 days) and troponin ≥ ULN and/or D-dimer ≥0.5 mg/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age below 18&#xD;
&#xD;
          -  Life expectancy less than 3 months before COVID-19&#xD;
&#xD;
          -  Resuscitation &gt; 30 minutes&#xD;
&#xD;
          -  Hypersensitivity to the active substance, to Edoxaban or any of its excipients&#xD;
&#xD;
          -  Significantly increased bleeding risk&#xD;
&#xD;
          -  Other indication for anticoagulation beyond COVID-19&#xD;
&#xD;
          -  GFR &lt; 15 ml/min&#xD;
&#xD;
          -  Planned transfer of the patient to another clinic within the next 42 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kluge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Kluge, MD</last_name>
    <phone>+49 40 7410</phone>
    <phone_ext>57010</phone_ext>
    <email>s.kluge@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahir Karakas, MD</last_name>
    <phone>+49 152 22817493</phone>
    <email>m.karakas@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bode, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Jörg Busch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienkrankenhaus</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Schäfer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitärsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kluge, MD</last_name>
      <email>s.kluge@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Welte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Köln-Merheim</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Karagiannidis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TU München Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Lahmer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hartmut Schmidt, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 6, 2020</study_first_submitted>
  <study_first_submitted_qc>September 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coagulopathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

